Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy

BACKGROUND: Nilotinib inhibits the tyrosine kinase activities of ABL1/BCR-ABL1, KIT, and platelet-derived growth factor receptors (PDGFRs). The results of a phase III clinical trial indicated that nilotinib could not be recommended for broad use as first-line therapy for gastrointestinal stromal tum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Surg Case Rep
Autors principals: Sugase, Takahito, Takahashi, Tsuyoshi, Ishikawa, Takashi, Ichikawa, Hiroshi, Kanda, Tatsuo, Hirota, Seiichi, Nakajima, Kiyokazu, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Yamasaki, Makoto, Takiguchi, Shuji, Wakai, Toshifumi, Mori, Masaki, Doki, Yuichiro
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5116018/
https://ncbi.nlm.nih.gov/pubmed/27864817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-016-0266-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars